Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer

Sekino,Yohei; Sakamoto,Naoya; Ishikawa,Akira; Honma,Ririno; Shigematsu,Yoshinori; Hayashi,Tetsutaro; Sentani,Kazuhiro; Oue,Naohide; Teishima,Jun; Matsubara,Akio; Yasui,Wataru

doi:10.3892/or.2019.7039

Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer

Authors:
- Yohei Sekino
- Naoya Sakamoto
- Akira Ishikawa
- Ririno Honma
- Yoshinori Shigematsu
- Tetsutaro Hayashi
- Kazuhiro Sentani
- Naohide Oue
- Jun Teishima
- Akio Matsubara
- Wataru Yasui
View Affiliations

Affiliations: Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan, Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima 734‑8551, Japan
Published online on: February 28, 2019 https://doi.org/10.3892/or.2019.7039
Pages: 3111-3118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (CDDP)‑based combination chemotherapy is the standard for muscle‑invasive bladder cancer (MIBC). However, nearly all patients undergoing CDDP chemotherapy become refractory due to the development of CDDP resistance. Therefore, clarification of the mechanisms of CDDP resistance is urgently needed. The transcribed ultraconserved regions (T‑UCRs) are a novel class of non‑coding RNAs that are highly conserved across species and are associated with carcinogenesis and cancer progression. In addition, emerging evidence has shown the involvement of androgen receptor (AR) signals in urothelial carcinoma (UC) progression. The aim of the present study was to investigate the expression of transcribed ultraconserved region Uc.63+, and to analyze the effects of Uc.63+ on AR expression and CDDP resistance in UC. Quantitative reverse transcription‑polymerase chain reaction (qRT‑PCR) revealed that the expression of Uc.63+ was higher in UC tissues than that in non‑neoplastic bladder tissues and 15 types of normal tissue. An MTT assay revealed that Uc.63+ was involved in cell proliferation. Western blotting demonstrated that the expression of AR was disrupted by the overexpression or knockdown of Uc.63+ in AR‑positive UMUC3 cells. Furthermore, knockdown of Uc.63+ increased sensitivity to CDDP in UMUC3 cells. Conversely, overexpression of Uc.63+ had no effect on CDDP sensitivity in AR‑negative RT112 cells. Additionally, we observed that the expression of Uc.63+ was increased in CDDP‑resistant UMUC3 cells (UMUC3‑CR) in comparison with that in parental UMUC3 cells. Knockdown of Uc.63+ re‑sensitized the UMUC3‑CR cells to CDDP. These results indicated that Uc.63+ may be a promising therapeutic target to overcome CDDP resistance in UC.

View Figures

View References

1	Lobo N, Mount C, Omar K, Nair R, Thurairaja R and Khan MS: Landmarks in the treatment of muscle-invasive bladder cancer. Nat Rev Urol. 14:565–574. 2017. View Article : Google Scholar : PubMed/NCBI
2	Keegan KA, Zaid HB, Patel SG and Chang SS: Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States. Curr Urol Rep. 15:3942014. View Article : Google Scholar : PubMed/NCBI
3	von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
4	Amable L: Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 106:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
5	Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel- Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
6	Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chandra Gupta S and Nandan Tripathi Y: Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967. 2017. View Article : Google Scholar : PubMed/NCBI
8	Taheri M, Omrani MD and Ghafouri-Fard S: Long non-coding RNA expression in bladder cancer. Biophys Rev. 10:1205–1213. 2017. View Article : Google Scholar : PubMed/NCBI
9	Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS and Haussler D: Ultraconserved elements in the human genome. Science. 304:1321–1325. 2004. View Article : Google Scholar : PubMed/NCBI
10	Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, Croce CM, Calin GA and Esteller M: CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene. 29:6390–6401. 2010. View Article : Google Scholar : PubMed/NCBI
11	Goto K, Ishikawa S, Honma R, Tanimoto K, Sakamoto N, Sentani K, Oue N, Teishima J, Matsubara A and Yasui W: The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation. Oncogene. 35:3598–3606. 2016. View Article : Google Scholar : PubMed/NCBI
12	Ferdin J, Nishida N, Wu X, Nicoloso MS, Shah MY, Devlin C, Ling H, Shimizu M, Kumar K, Cortez MA, et al: HINCUTs in cancer: Hypoxia-induced noncoding ultraconserved transcripts. Cell Death Differ. 20:1675–1687. 2013. View Article : Google Scholar : PubMed/NCBI
13	Marini A, Lena AM, Panatta E, Ivan C, Han L, Liang H, Annicchiarico-Petruzzelli M, Di Daniele N, Calin GA, Candi E, et al: Ultraconserved long non-coding RNA uc.63 in breast cancer. Oncotarget. 8:35669–35680. 2017. View Article : Google Scholar : PubMed/NCBI
14	Sekino Y, Sakamoto N, Goto K, Honma R, Shigematsu Y, Sentani K, Oue N, Teishima J, Matsubara A and Yasui W: Transcribed ultraconserved region Uc.63+ promotes resistance to docetaxel through regulation of androgen receptor signaling in prostate cancer. Oncotarget. 8:94259–94270. 2017.PubMed/NCBI
15	Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S, Dejima T, Todenhöfer T, Li N, Fazli L, et al: Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer. J Urol. 194:1120–1131. 2015. View Article : Google Scholar : PubMed/NCBI
16	Oue N, Naito Y, Hayashi T, Takigahira M, Kawano-Nagatsuma A, Sentani K, Sakamoto N, Zarni Oo H, Uraoka N, Yanagihara K, et al: Signal peptidase complex 18, encoded by SEC11A, contributes to progression via TGF-alpha secretion in gastric cancer. Oncogene. 33:3918–3926. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sekino Y, Oue N, Shigematsu Y, Ishikawa A, Sakamoto N, Sentani K, Teishima J, Matsubara A and Yasui W: KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer. Urol Oncol. 35:31 e13–31 e20. 2017. View Article : Google Scholar
18	Miyamoto H, Zheng Y and Izumi K: Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Targets. 12:14–22. 2012. View Article : Google Scholar : PubMed/NCBI
19	Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, et al: Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 99:558–568. 2007. View Article : Google Scholar : PubMed/NCBI
20	Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Kuroiwa K and Naito S: Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. J Urol. 188:276–286. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS and Miyamoto H: Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget. 7:49169–49179. 2016. View Article : Google Scholar : PubMed/NCBI
22	Fabris L and Calin GA: Understanding the genomic ultraconservations: T-UCRs and cancer. Int Rev Cell Mol Biol. 333:159–172. 2017. View Article : Google Scholar : PubMed/NCBI
23	Olivieri M, Ferro M, Terreri S, Durso M, Romanelli A, Avitabile C, De Cobelli O, Messere A, Bruzzese D, Vannini I, et al: Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget. 7:20636–20654. 2016. View Article : Google Scholar : PubMed/NCBI
24	Li Y, Izumi K and Miyamoto H: The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol. 42:569–577. 2012. View Article : Google Scholar : PubMed/NCBI
25	Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K and Eto M: Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5alpha-reductase inhibitor. J Urol. 197:308–313. 2017. View Article : Google Scholar : PubMed/NCBI
26	Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota J, Moriyama M, Murai T, Hayashi H, Inayama Y, Ohashi K, et al: Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget. 7:14153–14160. 2016. View Article : Google Scholar : PubMed/NCBI
27	Xiong Y, Wang L, Li Y, Chen M, He W and Qi L: The long non-coding RNA XIST interacted with MiR-124 to modulate bladder cancer growth, invasion and migration by targeting androgen receptor (AR). Cell Physiol Biochem. 43:405–418. 2017. View Article : Google Scholar : PubMed/NCBI
28	Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, et al: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 12:215–229. 2007. View Article : Google Scholar : PubMed/NCBI
29	Chen L, Chang WC, Hung YC, Chang YY, Bao BY, Huang HC, Chung WM, Shyr CR and Ma WL: Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line. Reprod Sci. 21:386–394. 2014. View Article : Google Scholar : PubMed/NCBI